Androgen-regulated gene expression in prostate cancer

Androgen-regulated gene expression is mediated by the ligand-activated androgen receptor. Androgen receptor target genes contain in the regulatory regions one or more androgen response elements. Development of the male urogenital tract, including the prostate, depends on an activated androgen recept...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in cancer biology 1997-02, Vol.8 (1), p.29-36
Main Authors: Trapman, Jan, Cleutjens, Kitty B.J.M.
Format: Article
Language:English
Subjects:
androgen receptor
Androgens - chemistry
Androgens - genetics
Androgens - physiology
Gene Expression Regulation
Humans
Male
Muscular Atrophy, Spinal
Mutation
Neoplasms, Hormone-Dependent - genetics
Neoplasms, Hormone-Dependent - metabolism
prostate cancer
prostate development
Prostatic Neoplasms - genetics
Prostatic Neoplasms - metabolism
Receptors, Androgen - genetics
Structure-Activity Relationship
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Androgen-regulated gene expression is mediated by the ligand-activated androgen receptor. Androgen receptor target genes contain in the regulatory regions one or more androgen response elements. Development of the male urogenital tract, including the prostate, depends on an activated androgen receptor. Similarly, growth of the majority of prostate cancers is androgen-dependent. Therefore, endocrine therapy, aimed at inhibition of androgen receptor functioning, has been applied for many years. However, during therapy, apparently androgen receptor independent cancers continue to grow. In general, these tumors still express the androgen receptor, suggesting a functional role of the androgen receptor. In a proportion of late stage prostate tumors, mutations and amplification of the androgen receptor gene have been found. Additionally, it has been hypothesized that ligand-independent androgen receptor activation can be involved in hormone refractory prostate cancer.
ISSN:1044-579X
1096-3650
DOI:10.1006/scbi.1997.0050